Tech Company Financing Transactions
Inflammatix Funding Round
Inflammatix closed a $32 million Series C funding round on 1/13/2020. Investors included Grey Sky Venture Partners, Khosla Ventures and Northpond Ventures.
Transaction Overview
Company Name
Announced On
1/13/2020
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series C
Investors
Proceeds Purpose
The funds will be used to advance Inflammatix's rapid HostDx tests through commercial launch in Europe and submission to the United States Food and Drug Administration in 2021.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
863 Mitten Rd. 104
Burlingame, CA 94010
USA
Burlingame, CA 94010
USA
Phone
Website
Email Address
Overview
Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. We are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 1/13/2020: Generation Bio venture capital transaction
Next: 1/13/2020: BioSkryb venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs